BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

Background The progression of prostate cancer to castration-resistant prostate cancer
(CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of …

Study Type–Therapy (cohort) Level of Evidence 2a What's known on the subject? and What
does the study add? Despite expanding treatment options for castration‐resistant prostate …

Background Few options are available after taxane-based therapy in men with CRPC.
Genetic alterations involving the mTOR pathway have been associated with CRPC …

Background Activation of the PI3K-Akt-mTOR signaling pathway is common in advanced
castration resistant prostate cancer (CRPC), typically through PTEN loss. Preclinical studies …

Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through
vascular endothelial growth factor (VEGF) have been shown to play important roles in …

Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Background Previous data suggests that co-targeting mammalian target of rapamycin and
angiogenic pathways may potentiate effects of cytotoxic chemotherapy. We studied …

BACKGROUND The effects of mammalian target of rapamycin (mTOR) inhibition are limited
by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin …